Bosniak 2019版IIF类囊性肾肿块的影像随访结局
本回顾性研究纳入219例患者共246个IIF类囊性肾肿块,评估Bosniak v2019分类IIF类肿块的时间演变。中位随访28.4个月,6个月随访时无升级,最终9个(4%)升级,升级中位时间53.5个月;切除10个肿块中4个恶性。结论认为IIF类肿块较少为侵袭性恶性肿瘤,初始6个月随访影像的临床价值存疑。
要点
- IIF类肿块6个月随访无升级,初始6个月复查临床价值存疑。
- 最终仅4%升级,升级中位时间53.5个月,均升至III或IV类。
- 切除肿块中4/10为恶性,其中3例术前仍为IIF类。
核心结论
- Bosniak v2019 IIF类囊性肾肿块不太可能代表侵袭性恶性肿瘤,仅4%随时间升级,且初始6个月随访从未发生升级。
- 目前推荐的IIF类肿块初始6个月随访影像检查的临床效用存疑。
研究设计与样本
- 回顾性研究,纳入2005年1月至2022年6月219例患者(女91例,男128例;中位年龄72岁)共246个局限性IIF类肿块。
- 患者均接受基线和至少一次随访肾脏肿块方案增强CT或MRI检查。
- 两名放射科医师评估所有随访时间点,第三名放射科医师解决分歧;评估降级、稳定或升级。
- 计算升级发生率,并对切除肿块评估组织病理学结局。
关键影像表现/征象
- 6个月随访时,5个(2%)肿块降级,241个(98%)稳定,无升级。
- 最终随访时,14个(6%)降级,223个(91%)稳定,9个(4%)升级。
- 所有升级事件均为分类升至III类(n=7)或IV类(n=2),无肿块变为实性或出现T3、N1、M1病变。
- 9个升级肿块的中位升级时间为53.5个月(IQR 23.2-63.7个月)。
诊断标准与关键数值
- 降级定义为分类降至I或II类;稳定定义为保持局限性IIF类;升级定义为分类升至III或IV类、变为实性或出现T3a、N1或M1及以上病变。
- 升级发生率为3.006/100,000人天(95%CI 1.466-5.516)。
- 10个肿块切除,组织病理学良性6个、恶性4个;4个恶性中1个术前随访15个月后升级为III类,3个术前随访仍为IIF类。
- 切除的恶性肿块无术后复发。
临床应用与阅片要点
- IIF类肿块随访中升级少见且发生较晚,初始6个月复查可能收益有限,可考虑优化随访间隔。
- 阅片时需注意IIF类肿块可长期稳定,但仍有少数晚期升级为III/IV类或恶性,需规范随访。
- 术前随访中部分恶性肿块仍表现为IIF类,提示影像分类存在假阴性可能,报告需谨慎。
局限性
- 回顾性研究设计。
- 中位随访28.4个月,部分肿块随访时间不足以观察晚期升级。
- 仅10个肿块获得组织病理学结果,恶性结局评估受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Bosniak classification system version 2019 (v2019) recommends that class IIF masses undergo follow-up imaging at 6 months, 12 months, and then annually for 5 years. The frequency and timing of upgrade on follow-up imaging are incompletely understood. OBJECTIVE. The purpose of this article is to describe the temporal evolution of Bosniak v2019 class IIF cystic renal masses, with attention to outcomes at 6-month follow-up, the time to class upgrade, and malignant histologic diagnoses. METHODS. This retrospective study included 219 patients (91 women, 128 men; median age, 72 years) with 246 localized class IIF masses from January 2005 to June 2022. Patients underwent both a baseline and at least one follow-up renal-mass protocol contrast-enhanced CT or MRI examination. Two radiologists evaluated masses at all follow-up time points to categorize masses as downgraded (class I or II), stable (localized class IIF), or upgraded (class III or IV, solid, or category T3a, N1, or M1 or higher disease); a third radiologist resolved discrepancies. Incidence rate of upgrade was determined. Histopathologic outcomes were assessed for resected masses. RESULTS. Median follow-up was 28.4 months (IQR, 13.7-59.4 months). At 6-month follow-up, five (2%) masses were downgraded, 241 (98%) were stable, and none were upgraded. On the basis of final follow-up, 14 (6%) masses were downgraded, 223 (91%) were stable, and nine (4%) were upgraded. All upgrade events entailed a class increase to III (n = 7) or IV (n = 2); no mass became solid or developed T3, N1, or M1 disease. Among the nine upgraded masses, median time to upgrade was 53.5 months (IQR, 23.2-63.7 months). Incidence rate of upgrade was 3.006 per 100,000 person-days (95% CI, 1.466-5.516). Ten masses were resected; histopathology was benign in six and malignant in four. Of the four malignant masses, one was upgraded to class III after 15 months of preoperative follow-up imaging, and three remained class IIF on preoperative follow-up imaging. No resected malignant mass developed postoperative recurrence. CONCLUSION. Bosniak v2019 class IIF masses are unlikely to represent aggressive malignancy; only 4% were upgraded over time and never on initial 6-month follow-up. CLINICAL IMPACT. The currently recommended initial 6-month follow-up imaging examination for class IIF masses is of questionable clinical utility.
引用
- Shen, Yoon, Chung, et al. Outcomes of Bosniak Classification Version 2019 Class IIF Cystic Renal Masses at Imaging Surveillance. AJR Am J Roentgenol. 2022. PMID: 36416398. doi:10.2214/AJR.22.28599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。